These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 19169608)

  • 1. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.
    Vici P; Viola G; Rossi S; Botti C; Vitucci C; Sergi D; Ferranti FR; Saracca E; Di Lauro L; Corsetti S; Foggi P; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):453-6. PubMed ID: 19169608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials.
    Estévez LG; Muñoz M; Alvarez I; Fernández Y; García-Mata J; Ruiz-Borrego M; Tusquets I; Seguí MA; Rodríguez-Lescure A; Adrover E; Lluch A
    Cancer Treat Rev; 2007 Aug; 33(5):474-83. PubMed ID: 17561350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
    Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
    J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
    Moreno-Aspitia A; Perez EA
    Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions.
    Tang SC
    Cancer Invest; 2009 Jun; 27(5):489-95. PubMed ID: 19479486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
    Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined anthracycline-taxane regimens in the adjuvant setting.
    Mamounas EP; Sledge GW
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):24-31. PubMed ID: 11552227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anthracyclines in the adjuvant treatment of breast carcinoma: thirty years later].
    Lopez M
    Clin Ter; 2006; 157(2):165-77. PubMed ID: 16817507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel activity, dose, and schedule: data from phase III trials in metastatic breast cancer.
    Di Leo A; Piccart MJ
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):27-32. PubMed ID: 10403471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of taxanes in breast cancer chemotherapy: what's new 15 years after?].
    Herceg D; Vrbanec D
    Lijec Vjesn; 2009; 131(5-6):133-41. PubMed ID: 19642533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and doxorubicin in metastatic breast cancer.
    Gehl J; Boesgaard M; Paaske T; Jensen BV; Dombernowsky P
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):35-8. PubMed ID: 8996596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer.
    Pal SK; Childs BH; Pegram M
    Breast Cancer Res Treat; 2010 Jan; 119(1):25-32. PubMed ID: 19795206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epirubicin in combination with the taxanes.
    Trudeau M; Pagani O
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):41-50. PubMed ID: 11552229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
    De Laurentiis M; Cancello G; D'Agostino D; Giuliano M; Giordano A; Montagna E; Lauria R; Forestieri V; Esposito A; Silvestro L; Pennacchio R; Criscitiello C; Montanino A; Limite G; Bianco AR; De Placido S
    J Clin Oncol; 2008 Jan; 26(1):44-53. PubMed ID: 18165639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
    J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer.
    Hortobagyi GN; Holmes FA
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S4-7. PubMed ID: 9071332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes.
    Murphy CG; Seidman AD
    Clin Breast Cancer; 2009 Jun; 9 Suppl 2():S58-65. PubMed ID: 19596644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Doxorubicin and paclitaxel vs. 5-fluorouracyl, doxorubicin and cyclophosphamid in the first line treatment of metastatic breast cancer].
    Nagykálnai T
    Magy Onkol; 2002; 46(2):192-3. PubMed ID: 12202899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.